シンバイオ製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/03/04 | 750 | 754 | 714 | 733 | -28 | -3.7% | 1,633,400 |
| 2022/03/03 | 799 | 803 | 759 | 761 | -15 | -1.9% | 1,631,900 |
| 2022/03/02 | 770 | 795 | 750 | 776 | -12 | -1.5% | 2,398,500 |
| 2022/03/01 | 803 | 824 | 772 | 788 | -9 | -1.1% | 3,794,000 |
| 2022/02/28 | 810 | 856 | 777 | 797 | +2 | +0.3% | 5,285,400 |
| 2022/02/25 | 730 | 795 | 712 | 795 | +100 | +14.4% | 5,029,100 |
| 2022/02/24 | 757 | 769 | 677 | 695 | -94 | -11.9% | 5,941,500 |
| 2022/02/22 | 800 | 827 | 767 | 789 | -42 | -5.1% | 2,695,500 |
| 2022/02/21 | 863 | 876 | 812 | 831 | -86 | -9.4% | 2,940,800 |
| 2022/02/18 | 930 | 951 | 882 | 917 | -45 | -4.7% | 2,897,000 |
| 2022/02/17 | 966 | 1,057 | 940 | 962 | +18 | +1.9% | 9,192,800 |
| 2022/02/16 | 914 | 944 | 899 | 944 | +150 | +18.9% | 3,221,000 |
| 2022/02/15 | 1,100 | 1,127 | 794 | 794 | -300 | -27.4% | 2,488,000 |
| 2022/02/14 | 1,104 | 1,190 | 1,094 | 1,094 | -190 | -14.8% | 3,017,700 |
| 2022/02/10 | 1,213 | 1,290 | 1,207 | 1,284 | +98 | +8.3% | 3,008,900 |
| 2022/02/09 | 1,135 | 1,188 | 1,116 | 1,186 | +51 | +4.5% | 1,296,600 |
| 2022/02/08 | 1,120 | 1,154 | 1,116 | 1,135 | +15 | +1.3% | 822,100 |
| 2022/02/07 | 1,139 | 1,143 | 1,103 | 1,120 | -15 | -1.3% | 794,000 |
| 2022/02/04 | 1,169 | 1,185 | 1,102 | 1,135 | +15 | +1.3% | 1,877,300 |
| 2022/02/03 | 1,112 | 1,123 | 1,065 | 1,120 | +28 | +2.6% | 1,236,600 |
| 2022/02/02 | 1,054 | 1,104 | 1,046 | 1,092 | +50 | +4.8% | 1,110,500 |
| 2022/02/01 | 1,020 | 1,075 | 1,018 | 1,042 | +36 | +3.6% | 1,297,900 |
| 2022/01/31 | 998 | 1,022 | 991 | 1,006 | +10 | +1% | 1,021,900 |
| 2022/01/28 | 1,005 | 1,007 | 984 | 996 | +6 | +0.6% | 642,500 |
| 2022/01/27 | 1,033 | 1,042 | 985 | 990 | -45 | -4.3% | 1,150,300 |
| 2022/01/26 | 998 | 1,043 | 997 | 1,035 | +44 | +4.4% | 917,000 |
| 2022/01/25 | 1,034 | 1,045 | 991 | 991 | -45 | -4.3% | 1,027,200 |
| 2022/01/24 | 1,003 | 1,037 | 996 | 1,036 | +15 | +1.5% | 601,300 |
| 2022/01/21 | 1,023 | 1,042 | 995 | 1,021 | -13 | -1.3% | 852,600 |
| 2022/01/20 | 997 | 1,041 | 995 | 1,034 | +25 | +2.5% | 787,100 |
| 2022/01/19 | 1,026 | 1,037 | 997 | 1,009 | -34 | -3.3% | 1,178,200 |
| 2022/01/18 | 1,043 | 1,089 | 1,032 | 1,043 | +8 | +0.8% | 914,800 |
| 2022/01/17 | 1,075 | 1,081 | 1,035 | 1,035 | -41 | -3.8% | 589,500 |
| 2022/01/14 | 1,081 | 1,091 | 1,066 | 1,076 | -25 | -2.3% | 924,000 |
| 2022/01/13 | 1,107 | 1,126 | 1,091 | 1,101 | -13 | -1.2% | 654,600 |
| 2022/01/12 | 1,095 | 1,125 | 1,091 | 1,114 | +38 | +3.5% | 1,264,800 |
| 2022/01/11 | 1,036 | 1,087 | 1,032 | 1,076 | +35 | +3.4% | 1,184,300 |
| 2022/01/07 | 1,075 | 1,084 | 1,027 | 1,041 | -30 | -2.8% | 1,078,500 |
| 2022/01/06 | 1,075 | 1,104 | 1,068 | 1,071 | -33 | -3% | 1,100,100 |
| 2022/01/05 | 1,155 | 1,155 | 1,094 | 1,104 | -54 | -4.7% | 1,368,400 |
| 2022/01/04 | 1,150 | 1,166 | 1,125 | 1,158 | +13 | +1.1% | 926,400 |
| 2021/12/30 | 1,127 | 1,152 | 1,107 | 1,145 | +4 | +0.4% | 966,900 |
| 2021/12/29 | 1,087 | 1,147 | 1,085 | 1,141 | +52 | +4.8% | 1,365,600 |
| 2021/12/28 | 1,118 | 1,122 | 1,070 | 1,089 | -21 | -1.9% | 1,314,500 |
| 2021/12/27 | 1,141 | 1,145 | 1,106 | 1,110 | -33 | -2.9% | 1,238,300 |
| 2021/12/24 | 1,145 | 1,173 | 1,137 | 1,143 | +6 | +0.5% | 1,103,000 |
| 2021/12/23 | 1,152 | 1,155 | 1,123 | 1,137 | -4 | -0.4% | 773,200 |
| 2021/12/22 | 1,121 | 1,157 | 1,104 | 1,141 | +25 | +2.2% | 1,209,100 |
| 2021/12/21 | 1,134 | 1,137 | 1,090 | 1,116 | +15 | +1.4% | 1,191,000 |
| 2021/12/20 | 1,160 | 1,186 | 1,100 | 1,101 | -80 | -6.8% | 1,696,100 |
851～
900
件表示中 / 3387件
類似銘柄と比較する
現在ご覧いただいている「シンバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| シンバイオ | 15,100円 | -42.9% | - | 0.00% | - | 3.64倍 |
|
導入で新薬開発・製品化。抗がん剤「トレアキシン」国内販売。抗ウイルス薬ＢＣＶの開発に注力 |
| ノイルイミューン | 18,900円 | -28.6% | - | 0.00% | - | 1.90倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| ケイファーマ | 69,500円 | - | - | 0.00% | - | 4.45倍 |
|
慶応大学発ベンチャー。ｉＰＳ細胞による再生医療と創薬の２本柱。中枢神経系が得意領域 |
| ＤＥＬＴＡ－Ｐ | 62,800円 | - | - | 0.00% | - | 26.32倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
| ティムス | 15,700円 | - | - | 0.00% | - | 2.56倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補を中国ＣＯＲＸＥＬ社に導出 |
市場注目の銘柄
チャート関連のコラム
